Immunomodulatory effects of chitosan nanoparticles as vaccine delivery agent against lymphatic filariasis through mucosal immunization.

Lymphatic filariasis is a parasitic disease caused by nematodes affecting millions of individuals in the tropical region. The complex life cycle of the filarial parasite eludes protective measures such as chemotherapy and vector control. Vaccination through recombinant proteins stands as one of the safe and most effective methods. The filarial antigens Brugia malayi Thioredoxin (TRX) and abundant larval transcript-2 (ALT-2) can induce recognizable levels of protection in murine animal models. Chitosan is a safe, non-toxic material ubiquitously served as an efficient carrier and an adjuvant. The present study was attempted to enhance the immune efficacy of filarial antigens using chitosan nanoparticles (CN) through mucosal routes of immunization. Our study showed that oral immunization was able to produce enhanced humoral response and balanced Th1/Th2 antibody isotype response for the recombinant antigens compared to intranasal routes. A high level of splenocyte T cell proliferation (P < 0.01) was obtained for both routes. The cytokine analysis showed a high level of IFN-γ followed by IL-5 for the oral route, whereas a high level of IL-4 was observed for intranasal route. These results confirm the ability of chitosan nanoparticles to elevate the immune efficacy of the antigens through the oral route in mice.